ArticleFrontiers in pediatrics2026
Case Report: Subcutaneous sensor-augmented insulin pump therapy in a 510-g preterm infant with hyperglycemia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal hyperglycemia affects up to 80% of extremely low birth weight (ELBW) infants and is independently associated with mortality, intraventricular hemorrhage, and adverse neurodevelopmental outcomes. Intravenous insulin infusion, which is the standard of care, requires dedicated vascular access. To the best of our knowledge, this is the first report of combined continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) in an ELBW infant (birth weight <1,000 g). Transient hyperglycemia developed on day of life (DOL) 2, necessitating insulin therapy. A 55-min intravenous bridge facilitated the transition to a subcutaneous sensor-augmented pump system (Medtronic MiniMed 780G; Guardian 4 CGM sensor; insulin aspart, undiluted). Given a subcutaneous adipose tissue depth of approximately 1-2 mm, standard insertion devices were not applicable; tangential near-horizontal manual insertion by a physician achieved reliable subcutaneous positioning. Over 14 days, 3,931 CGM measurements were recorded; the mean glucose level was 162 ± 57 mg/dL (9.0 ± 3.2 mmol/L), and the time in the target range (62-180 mg/dL; 3.4-10.0 mmol/L) was 59.4%. CGM reduced the number of invasive reference glucose measurements from an estimated 84-168 to 20, representing a 76%-88% reduction in cutaneous punctures. Infusion set occlusion on DOL 6 was identified prospectively using CGM trend analysis. Combined CGM and CSII were maintained uninterrupted throughout laparotomy for focal intestinal perforation, allowing real-time perioperative glycemic surveillance and proactive insulin dose titration without additional invasive procedures. Insulin therapy was discontinued on DOL 17 as glucose levels normalized. This case establishes proof-of-concept for sensor-augmented subcutaneous insulin pump therapy at the physiological extreme of viability, providing a procedural foundation for neonatal-adapted closed-loop trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.